Mersana Therapeutics’ (MRSN) Outperform Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN) in a report released on Monday,RTT News reports. They currently have a $4.00 price target on the stock.

MRSN has been the topic of a number of other reports. William Blair initiated coverage on Mersana Therapeutics in a research report on Thursday, February 6th. They set an “outperform” rating on the stock. Citigroup started coverage on Mersana Therapeutics in a research report on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.25.

Mersana Therapeutics Trading Up 0.8 %

Shares of MRSN opened at $0.51 on Monday. The company has a market capitalization of $63.30 million, a P/E ratio of -0.84 and a beta of 1.39. Mersana Therapeutics has a one year low of $0.46 and a one year high of $6.28. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. The stock has a 50-day moving average price of $0.79 and a 200 day moving average price of $1.56.

Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $16.36 million for the quarter, compared to the consensus estimate of $7.71 million. Sell-side analysts forecast that Mersana Therapeutics will post -0.62 EPS for the current fiscal year.

Institutional Trading of Mersana Therapeutics

Several large investors have recently added to or reduced their stakes in MRSN. US Bancorp DE acquired a new stake in Mersana Therapeutics in the 3rd quarter valued at approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Mersana Therapeutics during the 3rd quarter valued at $34,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Mersana Therapeutics during the 4th quarter valued at $37,000. Intech Investment Management LLC acquired a new position in shares of Mersana Therapeutics during the 3rd quarter valued at $52,000. Finally, Quarry LP acquired a new position in shares of Mersana Therapeutics during the 3rd quarter valued at $57,000. 93.92% of the stock is currently owned by institutional investors and hedge funds.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.